Credit: Calliditas. The conversion to regular approval was based on data from an additional 165 patients with biopsy-proven IgAN in the phase 3 NeflgArd trial. The conversion to regular approval was ...
TARPEYO (investigational name NEFECON) is the only FDA-approved treatment for IgAN to significantly reduce the loss of kidney function. TARPEYO is now approved with a confirmed and statistically ...
The conversion to regular approval was based on data from an additional 165 patients with biopsy-proven IgAN. The Food and Drug Administration (FDA) has granted full approval to Tarpeyo ® (budesonide) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results